Archivos de bronconeumologia · 2012
Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery.
СтатьяКлинические рекомендацииНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miravitlles Marc, Soler-Cataluña Juan José, Calle Myriam, Molina Jesús, Almagro Pere, Quintano José Antonio, Riesco Juan Antonio, Trigueros Juan Antonio, Piñera Pascual, Simón Adolfo, López-Campos José Luis, Soriano Joan B, Ancochea Julio, Spanish Society of Pulmonology and Thoracic Surgery
Аннотация
Recognizing the clinical heterogeneity of COPD suggests a specific therapeutic approach directed by the so-called clinical phenotypes of the disease. The Spanish COPD Guidelines (GesEPOC) is an initiative of SEPAR, which, together with the scientific societies involved in COPD patient care, and the Spanish Patient Forum, has developed these new clinical practice guidelines. This present article describes the severity classification and the pharmacological treatment of stable COPD. GesEPOC identifies four clinical phenotypes with differential treatment: non-exacerbator, mixed COPD-asthma, exacerbator with emphysema and exacerbator with chronic bronchitis. Pharmacological treatment of COPD is based on bronchodilation in addition to other drugs depending on the clinical phenotype and severity. Severity is established by the BODE/BODEx multidimensional scales. Severity can also be approximated by assessing airflow obstruction, dyspnea, level of physical activity and history of exacerbations. GesEPOC is a new, more individualized approach to COPD treatment according to the clinical characteristics of the patients.
Предметные рубрики MeSH
Adrenal Cortex HormonesAminopyridinesAnti-Bacterial AgentsAsthmaBenzamidesBronchitisBronchodilator AgentsChronic DiseaseComorbidityCyclopropanesDisease ProgressionDrug Therapy, CombinationExpectorantsHumansPhenotypePulmonary Disease, Chronic ObstructivePulmonary EmphysemaRespiratory System AgentsSeverity of Illness IndexSpainTheophyllinealpha 1-Antitrypsin